Drug intelligence / Profile preview

naphazoline + pheniramine

Development stage
Unknown
Lead developer
Alcon
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

**Naphazoline + pheniramine** is an ophthalmic combination drug containing a sympathomimetic vasoconstrictor (naphazoline) and a first-generation antihistamine (pheniramine). It is used as eye drops for the temporary relief of itching and redness associated with allergic conjunctivitis. - **Naphazoline** acts by constricting the blood vessels in the eye, thereby reducing redness and swelling. It is classified as a sympathomimetic amine (vasoconstrictor/decongestant). - **Pheniramine** is an H1 histamine receptor antagonist that blocks the action of histamine released during allergic reactions, relieving itching and irritation[1][3][6]. The combination is available over-the-counter and was first approved for clinical use in the United States in 1994[3].

Brand names
Naphcon-AOpcon-AVisine-AAK-Con-AVisine Multi-Action Eye Allergy Relief
Other names
naphazoline/pheniraminenaphazoline hydrochloride + pheniramine maleate
02

Targets

HRH4 (Histamine H4 receptor)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on naphazoline + pheniramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naphazoline + pheniramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call